TISIDB

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	-
Function	Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. Binds to the promoter region of its own gene and can activate its own transcription. Regulates the expression of key transcription factors during embryonic development. Plays an important role in maintaining embryonic stem cells, and in preventing their differentiation. Required for establishing the barrier function of the skin and for postnatal maturation and maintenance of the ocular surface. Involved in the differentiation of epithelial cells and may also function in skeletal and kidney development. Contributes to the down-regulation of p53/TP53 transcription.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001101 response to acid chemical GO:0001525 angiogenesis GO:0001654 eye development GO:0001667 ameboidal-type cell migration GO:0001704 formation of primary germ layer GO:0001707 mesoderm formation GO:0001709 cell fate determination GO:0001710 mesodermal cell fate commitment GO:0001818 negative regulation of cytokine production GO:0001933 negative regulation of protein phosphorylation GO:0002040 sprouting angiogenesis GO:0002042 cell migration involved in sprouting angiogenesis GO:0003012 muscle system process GO:0006644 phospholipid metabolic process GO:0006809 nitric oxide biosynthetic process GO:0006979 response to oxidative stress GO:0007159 leukocyte cell-cell adhesion GO:0007162 negative regulation of cell adhesion GO:0007369 gastrulation GO:0007423 sensory organ development GO:0007498 mesoderm development GO:0007500 mesodermal cell fate determination GO:0008544 epidermis development GO:0009791 post-embryonic development GO:0009913 epidermal cell differentiation GO:0010035 response to inorganic substance GO:0010466 negative regulation of peptidase activity GO:0010470 regulation of gastrulation GO:0010594 regulation of endothelial cell migration GO:0010596 negative regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010633 negative regulation of epithelial cell migration GO:0010951 negative regulation of endopeptidase activity GO:0010975 regulation of neuron projection development GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0014067 negative regulation of phosphatidylinositol 3-kinase signaling GO:0014738 regulation of muscle hyperplasia GO:0014740 negative regulation of muscle hyperplasia GO:0014745 negative regulation of muscle adaptation GO:0014900 muscle hyperplasia GO:0016055 Wnt signaling pathway GO:0016525 negative regulation of angiogenesis GO:0019216 regulation of lipid metabolic process GO:0019827 stem cell population maintenance GO:0020027 hemoglobin metabolic process GO:0022407 regulation of cell-cell adhesion GO:0022408 negative regulation of cell-cell adhesion GO:0030336 negative regulation of cell migration GO:0031077 post-embryonic camera-type eye development GO:0031099 regeneration GO:0031102 neuron projection regeneration GO:0031103 axon regeneration GO:0031348 negative regulation of defense response GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032102 negative regulation of response to external stimulus GO:0032526 response to retinoic acid GO:0032602 chemokine production GO:0032637 interleukin-8 production GO:0032642 regulation of chemokine production GO:0032677 regulation of interleukin-8 production GO:0032682 negative regulation of chemokine production GO:0032717 negative regulation of interleukin-8 production GO:0033002 muscle cell proliferation GO:0034113 heterotypic cell-cell adhesion GO:0034114 regulation of heterotypic cell-cell adhesion GO:0034115 negative regulation of heterotypic cell-cell adhesion GO:0034405 response to fluid shear stress GO:0034599 cellular response to oxidative stress GO:0034614 cellular response to reactive oxygen species GO:0034616 response to laminar fluid shear stress GO:0035019 somatic stem cell population maintenance GO:0035166 post-embryonic hemopoiesis GO:0040013 negative regulation of locomotion GO:0042035 regulation of cytokine biosynthetic process GO:0042036 negative regulation of cytokine biosynthetic process GO:0042089 cytokine biosynthetic process GO:0042107 cytokine metabolic process GO:0042228 interleukin-8 biosynthetic process GO:0042326 negative regulation of phosphorylation GO:0042541 hemoglobin biosynthetic process GO:0042542 response to hydrogen peroxide GO:0043010 camera-type eye development GO:0043154 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043388 positive regulation of DNA binding GO:0043409 negative regulation of MAPK cascade GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043491 protein kinase B signaling GO:0043500 muscle adaptation GO:0043502 regulation of muscle adaptation GO:0043534 blood vessel endothelial cell migration GO:0043535 regulation of blood vessel endothelial cell migration GO:0043537 negative regulation of blood vessel endothelial cell migration GO:0043542 endothelial cell migration GO:0043550 regulation of lipid kinase activity GO:0043551 regulation of phosphatidylinositol 3-kinase activity GO:0044057 regulation of system process GO:0045165 cell fate commitment GO:0045414 regulation of interleukin-8 biosynthetic process GO:0045415 negative regulation of interleukin-8 biosynthetic process GO:0045428 regulation of nitric oxide biosynthetic process GO:0045429 positive regulation of nitric oxide biosynthetic process GO:0045444 fat cell differentiation GO:0045765 regulation of angiogenesis GO:0045861 negative regulation of proteolysis GO:0045995 regulation of embryonic development GO:0046209 nitric oxide metabolic process GO:0046898 response to cycloheximide GO:0046984 regulation of hemoglobin biosynthetic process GO:0046985 positive regulation of hemoglobin biosynthetic process GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048332 mesoderm morphogenesis GO:0048333 mesodermal cell differentiation GO:0048514 blood vessel morphogenesis GO:0048569 post-embryonic animal organ development GO:0048659 smooth muscle cell proliferation GO:0048660 regulation of smooth muscle cell proliferation GO:0048662 negative regulation of smooth muscle cell proliferation GO:0048678 response to axon injury GO:0048679 regulation of axon regeneration GO:0048730 epidermis morphogenesis GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0051052 regulation of DNA metabolic process GO:0051054 positive regulation of DNA metabolic process GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051098 regulation of binding GO:0051099 positive regulation of binding GO:0051101 regulation of DNA binding GO:0051271 negative regulation of cellular component movement GO:0051346 negative regulation of hydrolase activity GO:0051896 regulation of protein kinase B signaling GO:0051898 negative regulation of protein kinase B signaling GO:0051972 regulation of telomerase activity GO:0051973 positive regulation of telomerase activity GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0060070 canonical Wnt signaling pathway GO:0060759 regulation of response to cytokine stimulus GO:0060761 negative regulation of response to cytokine stimulus GO:0060795 cell fate commitment involved in formation of primary germ layer GO:0061564 axon development GO:0061756 leukocyte adhesion to vascular endothelial cell GO:0061757 leukocyte adhesion to arterial endothelial cell GO:0070301 cellular response to hydrogen peroxide GO:0070371 ERK1 and ERK2 cascade GO:0070372 regulation of ERK1 and ERK2 cascade GO:0070373 negative regulation of ERK1 and ERK2 cascade GO:0070570 regulation of neuron projection regeneration GO:0070586 cell-cell adhesion involved in gastrulation GO:0070587 regulation of cell-cell adhesion involved in gastrulation GO:0071229 cellular response to acid chemical GO:0071300 cellular response to retinoic acid GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071409 cellular response to cycloheximide GO:0071417 cellular response to organonitrogen compound GO:0071498 cellular response to fluid shear stress GO:0071499 cellular response to laminar fluid shear stress GO:0071897 DNA biosynthetic process GO:0072567 chemokine (C-X-C motif) ligand 2 production GO:0072593 reactive oxygen species metabolic process GO:0090049 regulation of cell migration involved in sprouting angiogenesis GO:0090051 negative regulation of cell migration involved in sprouting angiogenesis GO:0090130 tissue migration GO:0090132 epithelium migration GO:0090257 regulation of muscle system process GO:0097305 response to alcohol GO:0097306 cellular response to alcohol GO:0098727 maintenance of cell number GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules GO:0198738 cell-cell signaling by wnt GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1901652 response to peptide GO:1901653 cellular response to peptide GO:1901654 response to ketone GO:1901655 cellular response to ketone GO:1902532 negative regulation of intracellular signal transduction GO:1903034 regulation of response to wounding GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903038 negative regulation of leukocyte cell-cell adhesion GO:1903409 reactive oxygen species biosynthetic process GO:1903426 regulation of reactive oxygen species biosynthetic process GO:1903428 positive regulation of reactive oxygen species biosynthetic process GO:1903670 regulation of sprouting angiogenesis GO:1903671 negative regulation of sprouting angiogenesis GO:1903725 regulation of phospholipid metabolic process GO:1904407 positive regulation of nitric oxide metabolic process GO:1904994 regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904997 regulation of leukocyte adhesion to arterial endothelial cell GO:1904998 negative regulation of leukocyte adhesion to arterial endothelial cell GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000117 negative regulation of cysteine-type endopeptidase activity GO:2000146 negative regulation of cell motility GO:2000181 negative regulation of blood vessel morphogenesis GO:2000278 regulation of DNA biosynthetic process GO:2000341 regulation of chemokine (C-X-C motif) ligand 2 production GO:2000342 negative regulation of chemokine (C-X-C motif) ligand 2 production GO:2000377 regulation of reactive oxygen species metabolic process GO:2000379 positive regulation of reactive oxygen species metabolic process GO:2000573 positive regulation of DNA biosynthetic process GO:2000677 regulation of transcription regulatory region DNA binding GO:2000679 positive regulation of transcription regulatory region DNA binding GO:2001057 reactive nitrogen species metabolic process
Molecular Function	GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001010 transcription factor activity, sequence-specific DNA binding transcription factor recruiting GO:0001047 core promoter binding GO:0001076 transcription factor activity, RNA polymerase II transcription factor binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001085 RNA polymerase II transcription factor binding GO:0001134 transcription factor activity, transcription factor recruiting GO:0001159 core promoter proximal region DNA binding GO:0001190 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001191 transcriptional repressor activity, RNA polymerase II transcription factor binding GO:0001221 transcription cofactor binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0008013 beta-catenin binding GO:0008134 transcription factor binding GO:0019207 kinase regulator activity GO:0035014 phosphatidylinositol 3-kinase regulator activity GO:0042826 histone deacetylase binding GO:0098811 transcriptional repressor activity, RNA polymerase II activating transcription factor binding
Cellular Component	GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0000791 euchromatin GO:0005667 transcription factor complex GO:0005719 nuclear euchromatin GO:0044454 nuclear chromosome part GO:0044798 nuclear transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome	R-HSA-1266738: Developmental Biology R-HSA-392499: Metabolism of proteins R-HSA-2980736: Peptide hormone metabolism R-HSA-422085: Synthesis, secretion, and deacylation of Ghrelin R-HSA-452723: Transcriptional regulation of pluripotent stem cells R-HSA-381340: Transcriptional regulation of white adipocyte differentiation

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KLF4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between KLF4 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
23737434	Breast Carcinoma	Inhibit immunity (T cell function)	Finally, we found that CXCL5/CXCR2 axis facilitated MDSC migration and that anti-GM-CSF antibodies neutralized CXCL5-induced accumulation of MDSCs. Taken together, our data suggest that KLF4 modulates maintenance of MDSCs in bone marrow by inducing GM-CSF production via CXCL5 and regulates recruitment of MDSCs into the primary tumors through the CXCL5/CXCR2 axis, both of which contribute to KLF4-mediated mammary tumor development.
28068326	Melanoma	Inhibit immunity	KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. We find that KLF4 is highly expressed in a subset of human melanomas. Ectopic expression of KLF4 enhances melanoma cell growth by decreasing apoptosis.

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KLF4 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KLF4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.267	0.566
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.148	0.927
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.596	0.501
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.424	0.545
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.783	0.724
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.026	0.993
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.057	0.904
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.361	0.763
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.521	0.692
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.097	0.303
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.811	0.221
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.17	0.263

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KLF4 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KLF4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KLF4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KLF4. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KLF4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KLF4 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KLF4 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KLF4
Name	Kruppel-like factor 4 (gut)
Aliases	EZF; GKLF; endothelial Kruppel-like zinc finger protein; epithelial zinc finger protein EZF; gut-enriched kr ......
Chromosomal Location	9q31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KLF4 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KLF4